Kidney trouble may skew chemo safety test – new study aims to fix that
NCT ID NCT07124403
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether kidney problems interfere with a common blood test used to check how well patients break down certain chemotherapy drugs (fluoropyrimidines). Researchers will measure DPD enzyme activity in about 742 people with breast or digestive cancer, kidney failure, or both. The goal is to make sure the test correctly identifies patients at risk of severe side effects, so doses can be adjusted safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- blood sampling
- What this could lead to
- If successful, this could help doctors personalize chemotherapy doses for patients with kidney disease, reducing severe side effects.
- What could go wrong
- This is an observational study, not a treatment trial. It may not change practice immediately, and results might not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?